2002: Prof. Stephen O'Rahilly

Boehringer Ingelheim donates Heinrich Wieland Prize for insights obesity and insulin resistance

Ingelheim, Germany, 8 November 2002 - The Heinrich Wieland Prize worth EUR 25,000 was awarded to Prof. Stephen O`Rahilly from the Departments of Medicine and Clinical Biochemistry at the University of Cambridge, United Kingdom, on 8 November 2002. The award ceremony took place at Ludwig Maximilians University in Munich, Germany.

Prof. Dieter Hinzen, head of Boehringer Ingelheim’s largest research and development center at Biberach, Germany, says: "This prize reflects our special relationship to Heinrich Wieland, who laid the foundations for Boehringer Ingelheim’s pharmaceutical research. The Heinrich Wieland Prize emphasises our commitment to scientific progress in research into metabolic diseases that leads to the development of innovative therapies.”

Prof. O’Rahilly conducts research into the molecular mechanisms in obesity and type II diabetes. His scientific achievements have mainly contributed to understanding the genetic causes of human obesity and insulin resistance. “This renowned award gives fresh recognition to the importance of research into obesity and diabetes - two of the world’s fastest-growing diseases, “ Prof. O’Rahilly said.

His work has illuminated the importance of several key regulatory molecules including leptin, the melanocortin 4 receptor and the nuclear receptor PPAR gamma to human physiology and metabolic disease.

The Heinrich Wieland Prize has been awarded annually since 1963 for scientific work in the fields of biochemistry, chemistry and physiology of fats and lipids and their clinical importance. This well-known international science award has gone to a total of 53 researchers. Boehringer Ingelheim has been responsible for this prize since 2001. The award is named after the German chemist and Nobel prize winner Prof. Heinrich Otto Wieland (1877 – 1957), a cousin of Boehringer Ingelheim‘s founder Albert Boehringer. Boehringer Ingelheim today has five research centers worldwide employing 4,500 scientists and related specialists.

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 144 affiliates in 45 countries and nearly 36,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2004, Boehringer Ingelheim posted net sales of 8.2 billion euro while spending nearly one fifth of net sales in its largest business segment Prescription Medicines on research and development.

Contact

Dr. Anja Hoffmann
Heinrich Wieland Prize

Boehringer Ingelheim Foundations
Schusterstr. 46-48
55116 Mainz/Germany

Tel. +49 (0)6131 / 27 50 815
hwp@boehringer-ingelheim-stiftung.de

Kirsten Achenbach
Communications

Boehringer Ingelheim Foundations
Schusterstr. 46-48
55116 Mainz/Germany

Tel. +49 (0)6131 / 27 50 816
kirsten.achenbach@bifonds.de

Go back

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .